Skip to content
Menu

Alpha Cognition Announces Publication Of US Patent Application Covering Benzgalantamine For Treating Persistent Post-Concussion Symptoms

Benzinga Newsdesk 5 hours ago

News

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative

Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent No. 20260325541-A1, titled "Benzgalantamine for Treating Persistent Post-Concussion Symptoms."

The published application includes pending claims directed to methods of treating persistent post-concussion symptoms with benzgalantamine. The application describes the use of benzgalantamine in patients experiencing persistent symptoms following mild traumatic brain injury, including cognitive impairment, and includes multiple routes of administration.

The publication expands Alpha Cognition’s intellectual property portfolio supporting the potential development of benzgalantamine for neurological conditions beyond Alzheimer’s disease. The application also includes preclinical data evaluating benzgalantamine in animal models of traumatic brain injury, including findings related to sensorimotor and cognitive recovery, neuronal preservation, neurogenesis, lesion volume, and pathological phosphorylated tau.

Read at benzinga.com